Phenprocoumon
Liquamar (phenprocoumon) is a small molecule pharmaceutical. Phenprocoumon was first approved as Liquamar on 1982-01-01. It is used to treat pulmonary embolism, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against vitamin K epoxide reductase complex subunit 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| venous thrombosis | HP_0004936 | D020246 | I82.40 |
| pulmonary embolism | HP_0002204 | D011655 | I26 |
| thromboembolism | HP_0001907 | D013923 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | 3 | 11 | 8 | 23 |
| Thrombosis | D013927 | — | — | — | 2 | 2 | 2 | 4 | 10 |
| Embolism | D004617 | — | — | — | — | 1 | 3 | 4 | 8 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | — | — | 1 | 2 | 4 | 7 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 3 | 3 | 6 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | 2 | 1 | 1 | 4 |
| Thromboembolism | D013923 | HP_0001907 | — | — | — | 1 | 1 | 2 | 4 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | — | 2 | 1 | 4 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 3 | — | 3 |
| Calcinosis | D002114 | — | — | — | — | — | 1 | 1 | 2 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | 2 | — | 3 | 5 |
| Neoplasms | D009369 | — | C80 | 1 | — | 1 | — | — | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Aortic dissection | D000784 | — | I71.0 | — | — | 1 | — | — | 1 |
| Internal carotid artery dissection | D020215 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial flutter | D001282 | EFO_0003911 | — | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular calcification | D061205 | — | — | — | — | — | — | 1 | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
| Hemostatic disorders | D020141 | — | — | — | — | — | — | 1 | 1 |
| Antiphospholipid syndrome | D016736 | EFO_0002689 | D68.61 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Phenprocoumon |
| INN | phenprocoumon |
| Description | Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting blood thinner drug to be taken by mouth, and a coumarin derivative. It acts as a vitamin K antagonist and inhibits blood clotting (coagulation) by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders such as heart attacks and pulmonary (lung) embolism. The most common adverse effect is bleeding. The drug interacts with a large number of other medications, including aspirin and St John's Wort. It is the standard coumarin used in Germany, Austria, and other European countries.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O |
Identifiers
| PDB | — |
| CAS-ID | 435-97-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1465 |
| ChEBI ID | 50438 |
| PubChem CID | 9908 |
| DrugBank | DB00946 |
| UNII ID | Q08SIO485D (ChemIDplus, GSRS) |
Target
Agency Approved
VKORC1
VKORC1
Organism
Homo sapiens
Gene name
VKORC1
Gene synonyms
VKOR
NCBI Gene ID
Protein name
vitamin K epoxide reductase complex subunit 1
Protein synonyms
phylloquinone epoxide reductase, vitamin K dependent clotting factors deficiency 2, Vitamin K1 2,3-epoxide reductase subunit 1, vitamin K1 epoxide reductase (warfarin-sensitive)
Uniprot ID
Mouse ortholog
Vkorc1 (27973)
vitamin K epoxide reductase complex subunit 1 (Q9CRC0)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,540 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,538 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use